In primary and metastatic prostate cancer, FZD Wnt receptor genetic mutations are relatively uncommon (<0.6% and 0.23–2.1%, respectively, Tables S1–S4), and although several FZD1-10 mutations have been shown to correlate with copy number alterations [64,65,66], it is not currently known if they alter Wnt receptor activity. Here, FZD1 is linked to metastatic prostate carcinoma.